Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat Accelerates Wound Healing in a Mouse Hind limb Lymphedema Model
Advances in Wound Care · 2025
DOI: 10.1089/wound.2024.0237 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Wound Care, 2025. Verfasst von Kosuke Ishikawa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic and Reconstructive Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. Hauptthemen laut MEDLINE: Wound Healing, Glycine, Lymphedema, Isoquinolines. Die Arbeit nennt 39 Literaturangaben.
Themen: Wundversorgung
Abstract (Originalsprache)
OBJECTIVE: Drugs regulating hypoxia-inducible factor (HIF)-1α have not been investigated for wound healing in lymphedema. Therefore, we examined the effects of drug modulation of HIF-1α activity for wound healing in our previously developed mouse model of nonirradiated hind limb lymphedema. APPROACH: Mouse hind limb lymphedema models (n = 17) and a sham group (n = 6) were created using 8- to 10-week-old male C57BL/6N mice. Mice with hind limb lymphedema were randomized into experimental groups receiving roxadustat, 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole (YC-1), or dimethyl sulfoxide and were given intraperitoneal injections every 2 days for up to 2 weeks. Four days after the surgery, an 8-mm diameter full-thickness skin wound was created in the hind limb. The number of days required for wound closure and the percentage of wounds closed were measured. Skin samples taken at wound creation were evaluated by histological and molecular analysis. RESULTS: Administration of roxadustat accelerated wound healing, whereas YC-1 delayed it, with a significant decrease and increase in skin thickness, respectively. The relative mRNA expression of Hif1α, matrix metalloproteinase-3, and interleukin-6 was significantly higher in the roxadustat group and that of metalloproteinase-9 was significantly lower in the roxadustat group compared with the control group. INNOVATION: This study is the first to demonstrate delayed wound healing in a mouse model of hind limb lymphedema and the first to demonstrate the promotion of significant wound healing through the use of roxadustat. CONCLUSION: Roxadustat exerts wound-healing effects and may promote the regulation of extracellular matrix remodeling via gene expression in hind limb lymphedema wound models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Plastic and Reconstructive Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
- Department of Plastic and Reconstructive Surgery, Center for Vascular Anomalies, Tonan Hospital, Sapporo, Japan.
ORCID-Profile: Kosuke Ishikawa, Yoshitada Hoshino, Emi Funayama, Takahiro Miura, Yuki Sasaki, Taku Maeda
Zitieren
APA
Ishikawa, K., Hoshino, Y., Osawa, M., Funayama, E., Miura, T., Hojo, M., Sasaki, Y., Sasaki, S., Yamamoto, Y., & Maeda, T. (2025). Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat Accelerates Wound Healing in a Mouse Hind limb Lymphedema Model. Advances in Wound Care. https://doi.org/10.1089/wound.2024.0237
Vancouver
Ishikawa K, Hoshino Y, Osawa M, Funayama E, Miura T, Hojo M, et al. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat Accelerates Wound Healing in a Mouse Hind limb Lymphedema Model. Advances in Wound Care. 2025. doi:10.1089/wound.2024.0237
BibTeX
@article{Ishikawa2025,
author = {Ishikawa, Kosuke and Hoshino, Yoshitada and Osawa, Masayuki and Funayama, Emi and Miura, Takahiro and Hojo, Masahiro and Sasaki, Yuki and Sasaki, Satoru and Yamamoto, Yuhei and Maeda, Taku},
title = {Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat Accelerates Wound Healing in a Mouse Hind limb Lymphedema Model},
journal = {Advances in Wound Care},
year = {2025},
doi = {10.1089/wound.2024.0237}
}
EUVIMED